Trial Profile
An Open-label, Multicenter Phase I Study to Characterize the Safety, Tolerability, Preliminary Anti-tumor Activity, Pharmacokinetics and Maximum Tolerated Dose of BAY1251152 in Patients With Advanced Hematological Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Feb 2021
Price :
$35
*
At a glance
- Drugs Enitociclib (Primary)
- Indications Acute myeloid leukaemia; Haematological malignancies
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bayer
- 24 Feb 2021 According to a Vincerx Pharma media release, it will be hosting a key opinion leader (KOL) meeting on VIP152 for the treatment of hematologic and solid tumors on Friday, March 5, 2021
- 03 Sep 2018 Status changed from active, no longer recruiting to completed.
- 20 Jul 2018 Planned End Date changed from 9 Jul 2018 to 6 Aug 2018.